NCT04282187 2026-03-16Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsUniversity of WashingtonPhase 2 Recruiting25 enrolled
NCT04817007 2025-09-10A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Bristol-Myers SquibbPhase 1/2 Active not recruiting216 enrolled